CVM Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 Mai 2024 @ 22:00):

Stats
Tagesvolumen	133 298
Durchschnittsvolumen	302 678
Marktkapitalisierung	79.89M
EPS	$0 ( 2024-02-13 )
Nächstes Ertragsdatum	( $-0.140 ) 2024-05-10
Last Dividend	$0.250 ( 1996-08-28 )
Next Dividend	$0 ( N/A )
P/E	-2.14
ATR14	$0.00600 (0.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Gobbo Mario	Sell	0	Common Stock
2024-04-19	Gobbo Mario	Sell	64 000	Options
2024-04-19	Watson Robert Eugene	Buy	64 000	Options
2024-04-19	Baillavoine Bruno Jean-marie	Buy	64 000	Options
2024-04-19	Talor Eyal	Buy	182 000	Options

INSIDER POWER
90.70
Last 100 transactions
Buy: 5 618 116 \| Sell: 153 000

Volumen Korrelation

Lang: 0.30 (neutral)

Kurz: 0.47 (neutral)

Signal:(59.008) Neutral

CEL-SCI Corp Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

CEL-SCI Corp Korrelation - Währung/Rohstoff

0.54
( weak )

0.85
( strong )

0.00
( neutral )

0.46
( neutral )

-0.74
( moderate negative )

CEL-SCI Corp Finanzdaten

Annual	2023
Umsatz:	$0
Bruttogewinn:	$-3.96M (0.00 %)
EPS:	$-0.720

FY	2023
Umsatz:	$0
Bruttogewinn:	$-3.96M (0.00 %)
EPS:	$-0.720

FY	2022
Umsatz:	$0
Bruttogewinn:	$-3.88M (0.00 %)
EPS:	$-0.890

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.900

Financial Reports:

No articles found.

CEL-SCI Corp Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

CEL-SCI Corp Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.250	1996-08-28
Last Dividend	$0.250	1996-08-28
Next Dividend	$0	N/A
Payout Date	2017-06-15
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.250	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-03)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for AMEX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
PLYM-PA	No Dividend Player	2023-08-24	Sporadic	0.00%
DFAS	Ex Dividend Junior	2023-09-19	Quarterly	0.00%
IAF	Ex Dividend Knight	2023-08-23	Quarterly	0.00%
NRO	Ex Dividend Knight	2023-09-14	Monthly	0.00%
CMCL	Ex Dividend Junior	2023-07-13	Quarterly	0.00%
GLQ	Ex Dividend Knight	2023-09-21	Monthly	0.00%
VFL	Ex Dividend Knight	2023-09-21	Monthly	0.00%
BTG	Ex Dividend Knight	2023-09-20	Quarterly	0.00%
FCO	Ex Dividend Knight	2023-09-21	Monthly	0.00%
NBW	Ex Dividend Knight	2023-09-28	Monthly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-1.087	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-2.05	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.264	0.800	8.68	6.94	[1 - 3]
quickRatioTTM	0.184	0.800	-3.62	-2.90	[0.8 - 2.5]
cashRatioTTM	0.666	1.500	7.41	10.00	[0.2 - 2]
debtRatioTTM	0.456	-1.500	2.40	-3.59	[0 - 0.6]
interestCoverageTTM	-42.08	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.476	2.00	-0.159	-0.317	[0 - 30]
freeCashFlowPerShareTTM	-0.484	2.00	-0.242	-0.484	[0 - 20]
debtEquityRatioTTM	1.035	-1.500	5.86	-8.79	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-1.761	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-2.64

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.20	1.000	-0.324	0	[1 - 100]
returnOnEquityTTM	-2.05	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.484	2.00	-0.161	-0.484	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.476	2.00	-0.159	-0.317	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0157	1.500	-3.23	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-1.831

CEL-SCI Corp

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.